Announcement related-TTianjin Tianyao Pharmaceuticals Co., Ltd.

Home Home

About us About us

Our business Our business

News and Information News and Information

Chinese

English

News and Information

News and Information

Announcement related

Tianjin Pharmaceutical's subsidiary's two peritoneal dialysis fluid products have passed evaluation, boosting its market competitiveness.

On July 29, Tianjin Pharmaceutical Group Co., Ltd. issued an announcement stating that its subsidiary, Tianjin Pharmaceutical Heping Co., Ltd., received the "Approval Notice for Supplementary Application for Drug" issued by the National Medical Products Administration for its peritoneal dialysis solution (lactate), approving the product's compliance with the generic drug quality and efficacy consistency evaluation. It is understood that this product is suitable for patients with acute and chroni

2025-07-29
Tianjin Pharmaceutical Group's subsidiary's low-calcium peritoneal dialysis solution has passed evaluation, indicating a broad market potential.

On June 26, Tianjin Pharmaceutical Group Co., Ltd. issued an announcement stating that its subsidiary, Tianjin Pharmaceutical Peace, received the "Approval Notice for Supplementary Application for Drug" issued by the National Medical Products Administration (NMPA) for its low-calcium peritoneal dialysis solution, approving the product's compliance with the generic drug quality and efficacy consistency evaluation. It is understood that low-calcium peritoneal dialysis solution is suitable for pati

2025-06-26
Methylprednisolone sodium succinate for injection has obtained a registration certificate from the Ministry of Health of the Dominican Republic.

Recently, Tianjin Pharmaceutical Group's subsidiary, Tianjin Pharmaceutical Peace, received a registration certificate from the Ministry of Health of the Dominican Republic for its injectable methylprednisolone sodium succinate (specifications: 125mg and 500mg), signifying that it can now manufacture and sell the drug in the Dominican Republic. Injectable methylprednisolone sodium succinate is a glucocorticoid primarily used for anti-inflammatory treatment, immunosuppressive therapy, treatment o

2025-05-07
Hydrocortisone sodium succinate for injection has obtained a drug registration certificate.

On April 24, Tianjin Pharmaceutical Group Co., Ltd. issued an announcement stating that its subsidiary, Tianjin Pharmaceutical Peace, received a Drug Registration Certificate for Hydrocortisone Sodium Succinate for Injection issued by the National Medical Products Administration. It is understood that this drug is used to treat critically ill patients with conditions such as toxic infections, anaphylactic shock, severe adrenocortical insufficiency, connective tissue diseases, and severe bronchia

2025-04-24
Tianjin Pharmaceutical Group's subsidiary obtains drug registration certificate for naloxone hydrochloride injection.

On the evening of March 17, Tianjin Pharmaceutical Group Co., Ltd. issued an announcement stating that its subsidiary, Hubei Tianjin Pharmaceutical Co., Ltd., received a Drug Registration Certificate for Naloxone Hydrochloride Injection issued by the National Medical Products Administration (NMPA). This drug is an opioid receptor antagonist. In August 2023, Hubei Tianjin Pharmaceutical submitted a registration application for this drug to the Center for Drug Evaluation of the NMPA, which was acc

2025-03-18
Tianjin Pharmaceutical Group successfully passed the US FDA CGMP on-site inspection.

Recently, Tianjin Pharmaceutical Group Co., Ltd. received an Establishment Inspection Report (EIR) from the U.S. FDA, indicating that its production site (No. 19, Xinyejiu Street, West Zone, Tianjin Economic-Technological Development Area) has passed the CGMP (Current Good Manufacturing Practice) on-site inspection. Tianjin Pharmaceutical Group underwent a CGMP (Current Good Manufacturing Practice) on-site inspection by the U.S. Food and Drug Administration (FDA) from December 9th to December 13

2025-03-13
Tianjin Pharmaceutical Group's subsidiary, Formoterol Fumarate Inhalation Solution, has obtained a drug registration certificate.

On the evening of January 21, Tianjin Pharmaceutical Group Co., Ltd. (Tianjin Pharmaceutical) announced that its subsidiary, Tianjin Pharmaceutical Heping, had received a drug registration certificate from the National Medical Products Administration (NMPA) for its formoterol fumarate inhalation solution. This drug is indicated for maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), primarily used for chronic bronchitis and emphysema. It is understood that Tianji

2025-01-22

<123 >|go toPage

Company Profile

Development History

Active Pharmaceutical Ingredient

Finished Dosage Forms

Exhibition and Events

News and Information

Contact Us

Sales of Active Pharmaceutical Ingredients

API Sales

API Marketing Center - Overseas Sales Division - API Sales Dept.

Tel: +86-022-65277510

Email: tianfa@tjpc.com.cn

Jinyao Pharmaceuticals (Singapore) PTE. LTD.

Tel: +65 6514 0579

Dar Sheng Trade & Technic Development Co. Ltd.

Tel: +1 (973) 218-2536

Sales of Finished Dosage Forms

FDF Sales

API Marketing Center - Overseas Sales Division - FDF Sales Dept.

Tel: +86 13902093969

Email: lizhao@vip.tjpc.com.cn

Hubei Jinyao foreign Trade Department

Tel: 0710-3227740

● Follow us

Official Accounts

Scan and follow us

津ICP备2024020218号-1 互联网药品信息备案凭证备案号：2023010016

Technical Support: jinkuncms This site supports IPV6

Cancel

添加微信好友，详细了解产品

使用企业微信
“扫一扫”加入群聊

复制成功

添加微信好友，详细了解产品

我知道了